Solara Active Pharma Sciences Intrinsic Value
SOLARA • Healthcare
Current Stock Price
₹476.10
Primary Intrinsic Value
₹548.50
Market Cap
₹1904 Cr
+30.5%
Upside
Median Value
₹621.20
Value Range
₹350 - ₹628
Assessment
Trading Below Calculated Value
Safety Margin
23.4%
SOLARA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹548.50 | ₹493.65 - ₹603.35 | +15.2% | Book Value/Share: ₹274.25, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹628.00 | ₹565.20 - ₹690.80 | +31.9% | Revenue/Share: ₹314.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹350.00 | ₹315.00 - ₹385.00 | -26.5% | EBITDA: ₹140.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹621.20 | ₹496.96 - ₹745.44 | +30.5% | CF Growth: 10.9%, Discount: 15% |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
SOLARA Intrinsic Value Analysis
What is the intrinsic value of SOLARA?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Solara Active Pharma Sciences (SOLARA) is ₹621.20 (median value). With the current market price of ₹476.10, this represents a +30.5% variance from our estimated fair value.
The valuation range spans from ₹350.00 to ₹628.00, indicating ₹350.00 - ₹628.00.
Is SOLARA undervalued or overvalued?
Based on our multi-method analysis, Solara Active Pharma Sciences (SOLARA) appears to be trading below calculated value by approximately 30.5%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.82 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -3.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.56x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Solara Active Pharma Sciences
Additional stock information and data for SOLARA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹213 Cr | ₹195 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹109 Cr | ₹107 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹156 Cr | ₹116 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-242 Cr | ₹-364 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹156 Cr | ₹103 Cr | Positive Free Cash Flow | 8/10 |